实用临床医药杂志2025，Vol.29Issue(24)：7-11,5.DOI:10.7619/jcmp.20255177
卡瑞利珠单抗联合培美曲塞、卡铂治疗晚期肺腺癌的疗效:一项随机对照试验
Efficacy of camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced lung adenocarcinoma:a randomised controlled trial
摘要
Abstract
Objective To analyze the efficacy of camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced lung adenocarcinoma and its impact on serum interferon-γ(IFN-γ)and galectin-3(Gal-3)levels.Methods A total of 197 patients with advanced lung ade-nocarcinoma admitted from January 2023 to January 2024 were selected as the study subjects.They were randomly divided into chemotherapy-alone group(n=98,pemetrexed+carboplatin)and cam-relizumab group(n=99,camrelizumab+pemetrexed+carboplatin)using a simple randomisation method.The efficacy,serum tumour-related factors[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)],immune function indicators[CD3+,CD4+,CD4+/CD8+],serum-related factors(IFN-γ,Gal-3),and safety were compared between the two groups.Results The objective response rate(ORR)and disease control rate(DCR)in the camrelizumab group were higher than those in the chemotherapy-alone group,with statistically significant differences(P＜0.05).The lev-els of CEA,CA125,and Gal-3 after treatment decreased in both groups,and their levels in the cam-relizumab group were lower than those in the chemotherapy-alone group,with statistically significant differences(P＜0.05).The levels of CD3+,CD4+,CD4+/CD8+,and IFN-γ increased in both groups,and the levels in the camrelizumab group were higher than those in the chemotherapy-alone group,with statistically significant differences(P＜0.05).After treatment,the scores of psycho-logical,social,physical function,and material life increased in both groups,and their scores in the camrelizumab group were higher than those in the chemotherapy-alone group,with statistically sig-nificant differences(P＜0.05).There was no statistically significant difference in the overall inci-dence of adverse reactions such as gastrointestinal reactions,rash,nausea,and vomiting between the camrelizumab group and the chemotherapy-alone group(P＜0.05).Conclusion Camrelizumab combined with pemetrexed and carboplatin has significant clinical efficacy in the treatment of ad-vanced lung adenocarcinoma.It can effectively reduce Gal-3 and tumour-related factors levels,in-crease IFN-γ levels and immune function,and does not increase adverse reactions.关键词
卡瑞利珠单抗/肺腺癌/免疫疗法/半乳糖凝集素3/随机对照试验/肿瘤微环境/生物标志物/生存率Key words
camrelizumab/lung adenocarcinoma/immunotherapy/galectin-3/randomised controlled trial/tumor microenvironment/biomarker/survival rate分类
医药卫生引用本文复制引用
张春玲,孙晓,李治岐,左燕雨,李英霞,段东奎,张琳..卡瑞利珠单抗联合培美曲塞、卡铂治疗晚期肺腺癌的疗效:一项随机对照试验[J].实用临床医药杂志,2025,29(24):7-11,5.基金项目
河南省医学科技攻关计划项目(LHGJ20200907) （LHGJ20200907）
